Search results
Showing 1 to 9 of 9 results for bicalutamide
In development Reference number: GID-TA11557 Expected publication date: 11 September 2025
In development Reference number: GID-TA11730 Expected publication date: 05 November 2025
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
View recommendations for TA721Show all sections
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.